TECHWIRE 30
(CIX: WRAL30)  989.76  up arrow+0.9  (0.09 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Apple)  519.01  up arrow+1.05  (0.2 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: QUINTILES)  50.60    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(OP: BASF SE)  108.14    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: BioCryst)  8.34    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: BioDelivery)  7.40    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: CEMP)  9.23    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Cisco Systems)  23.03    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Cornerstone)  9.49    (0 %)  Updated: 08:10 PM EST, Feb 03 2014
(NQ: Cree)  56.38    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: DARA)  2.48    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: EMC CORPORATION)  26.70    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: Extreme Networks)  5.62    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Facebook)  59.72  up arrow+0.63  (1.07 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: GLAXOSMITHKLINE)  52.82    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: GOOG)  556.54    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: IBM)  196.40    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NY: LH)  101.95    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(OP: Lenovo Group)  24.14    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: MRK)  56.26    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: Microsoft Corp)  40.40    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: NetApp)  36.24    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: NOVARTIS AG)  84.41    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(OP: Novozymes A/S)  44.91    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: PFIZER)  30.09    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: Pozen)  8.73    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: RED HAT)  50.62    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: BBRY)  7.15    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Salix)  100.66    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: SQI)  26.00    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014

Posts tagged “Pozen”

Updated March 5

Premium Lock Raleigh M2M firm sold; Metabolon's new deal; Red Hat expands 'cloud;' FDA nod for OxyBio; Pozen cuts losses; reboot costs TransEnterix

Bulldog In today's Bullbog blog rounding up the latest tech and life science news: Raleigh-based Jazz Wireless is sold; Metabolon makes a deal with Craig Venter firm; Red Hat joins AWS GovCloud; Oxygen Biotherapeutics can advance research on brain treatment; Pozen cuts its losses; and TransEnterix losses mount as company reboots.

January 3

Premium Lock In the news: Alicia Keys and Blackberry; Pozen; Hyundai and Google Glass; Facebook suit; Google cartoon patent

Bulldog Bulldog Blog: The latest technology news includes Blackberry parting ways with singer Alicia Keys; Hyundai offering Google Glass apps; Facebook faces a privacy suit over scanning of messages; and Google wins a patent for creating comic strips on social networks; Pozen promotes an executive.

December 23, 2013

Premium Lock Pozen's 'safer aspirin' delayed pending additional clinical study

Pozen will conduct a phase I trial comparing two dosages of its safer aspirin in order to answer FDA questions about its effects. Read more about the additional clinical study.

Chairman, CEO John Plachetka Chairman, CEO John Plachetka

Updated November 19, 2013

Premium Lock Payday for Pozen as Horizon acquires U.S. rights to pain drug Vimovo

With a sales force already dedicated to selling an osteoarthritis drug, Horizon Pharma is better suited to selling Pozen's pain drug Vimovo. Read more about how Pozen benefits from the deal.

Chairman, CEO John Plachetka Chairman, CEO John Plachetka

Updated November 19, 2013

Premium Lock Now that's a relief: Pain reliever deal means guaranteed minimum royalties to Pozen

The key to the deal for Pozen is guaranteed minimum royalty payments for Vimovo, an osteo-arthritis drug, the Chapel Hill-based company says.

Arthritis  Arthritis

November 7, 2013

Premium Lock With cardiovascular drug partnered, cancer becomes Pozen's next target

After landing Sanofi as a drug partner to commercialize its cardiovascular drug, Pozen is now pursuing a drug partner in cancer. Read why Pozen believes cancer is the next best opportunity for the company.

Diagram from Pozen presentation about PA technology Diagram from Pozen presentation about PA technology

Updated September 19, 2013

Premium Lock Is Pozen-AstraZeneca partnership unraveling? Firms amend sales-challenged arthritis drug Vimovo deal

Chapel-Hill based Pozen and AstraZeneca have amended their agreement on osteo-arthritis drug Vimovo, paving the way for what could be an unraveling of a drug partnership dating to 2006. Sales have disappointed both firms.

How Vimovo works How Vimovo works

Updated September 19, 2013

Premium Lock Tech Venture event showcases Triangle's possible next wave of IPOs

Early-stage startups seeking money weren't the only companies taking the stage at CED's Tech Venture Conference. WRALTechWire Insiders can read all about six companies that have grown from upstarts to stalwarts in their respective sectors. Will Bronto, Netsertive, Overture, ReverbNation, StrikeIron and WebAssign someday go the IPO route?

ReverbNation's Michael Doernberg ReverbNation's Michael Doernberg

Updated September 6, 2013

Premium Lock Pozen's 'safer aspirin' expected to ride on Sanofi's Plavix success

Pozen believes that Sanofi is the best possible big pharma partner to sell its 'safer on the stomach' aspirin. Read how this drug will fits in Sanofi's drug portfolio.

Chairman, CEO John Plachetka Chairman, CEO John Plachetka

August 6, 2013

Premium Lock Cornerstone Therapeutics turns corner to profitability on record drug sales

Cornerstone Therapeutics Sales for Cornerstone Therapeutics were up 88 percent in the second quarter compared to a year ago.

Updated August 6, 2013

Premium Lock Pozen still seeking drug partner while FDA reviews its 'safer aspirin'

While Pozen works on landing a drug partner to market its prospective new heart drug, it's now starting to look like Pozen might need global partners. Read more about the company's status.

Diagram from Pozen presentation about PA technology Diagram from Pozen presentation about PA technology

May 29, 2013

Premium Lock Safer aspirin from Pozen accepted for FDA review

Pozen An FDA approval decision on Pozen's PA drug could come by early January.

Updated May 8, 2013

Premium Lock AstraZeneca's decision to stop pain drug's promotion leaves Pozen considering new partners

AstraZeneca's decision to stop promoting arthritis drug Vimovo in key markets leaves drug partner Pozen figuring out its options for what is currently its top-selling product. What might the company do?

How Vimovo works How Vimovo works

May 8, 2013

Premium Lock Pozen's painful partner news triggers 15% drop in stock price

Pozen Shares plunged Wednesday after the Chapel Hill-based pharmaceutical firm discloses in its quarterly financial report that a big drug partner is going to stop selling the company's big money maker in the U.S. and parts of Europe. What does this mean for Pozen?

Updated May 8, 2013

Premium Lock Latest pain for Pozen: AstraZeneca to stop sales of its pain reliever in US

Pozen The Chapel Hill-based pharmaceutical firm discloses in its quarterly financial report that a big drug partner is going to stop selling the company's big money maker in the U.S. and parts of Europe. What does this mean for Pozen and its shareholders?

March 27, 2013

Premium Lock Safer aspirin from Pozen filed for FDA approval

FDA A safer-on-the-stomach aspirin developed by Pozen has been submitted to the Food and Drug Administration for regulatory approval

Updated March 12, 2013

Premium Lock Pozen's drug combination patent maintained in Europe

Pozen CEO John Plachetka European patents for Pozen's combination drug technology are valid and will continue to stand, according to a decision issued by European patent authorities.

March 6, 2013

Premium Lock Pozen pain reliever sales, royalties surge in 2012

Pozen Sales of Vimovo, a pain reliever sold by partner AstraZeneca, surged in 2012, thus delivering a growing revenue stream to Chapel Hill-based Pozen. But the company still posted a $25 million dollar loss.

November 8, 2012

Premium Lock Earnings: Salix; PowerSecure; Pozen; BioCryst

Bulldog Inside the Bulldog Blog: Revenues up at Salix; record revenues for PowerSecure; Pozen cuts losses; net loss declines at Biocryst;

November 7, 2012

Premium Lock Pozen reports positive test results for proposed aspirin therapy

Pozen Results from two Phase 3 clinical trials for its proposed aspirin therapy are positive, Chapel Hill-based Pozen says.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Scroll